Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNTOCINON vs OXYTOCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, stimulating G-protein coupled receptor activation and increasing intracellular calcium, leading to uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to induce milk ejection.
Induction or augmentation of labor,Facilitation of abortion in the second trimester,Postpartum hemorrhage prevention and treatment
Induction of labor for medical necessity,Augmentation of labor to enhance uterine contractions,Postpartum hemorrhage prevention and treatment,Incomplete abortion adjunct (off-label),Lactation support (off-label)
10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.
For induction/augmentation of labor: IV infusion, initial 0.5-2 m U/min, increase by 1-2 m U/min every 30-60 min until desired contraction pattern; max 20 m U/min. For postpartum hemorrhage: IV bolus 3 units (slow push) or IV infusion 10-40 units in 1000 m L crystalloid, rate adjusted to control bleeding; alternatively IM 10 units after delivery of placenta.
Terminal elimination half-life: 1–6 minutes (intravenous); 1–9 minutes (intramuscular). Clinically, effects dissipate rapidly after infusion cessation.
Terminal elimination half-life: 1–6 minutes (intravenous); clinical context: rapid offset requires continuous infusion for sustained uterine contraction.
Rapidly metabolized in the liver and kidneys by oxytocinase (cysteine aminopeptidase) and other peptidases.
Primarily metabolized by oxytocinase (leucyl-cystinyl aminopeptidase) in the liver and kidney, and by placental oxytocinase during pregnancy. Excreted renally.
Renal: >99% as intact oxytocin; biliary/fecal: negligible (<1%).
Renal: >99% as intact oxytocin and metabolites; biliary/fecal: negligible.
Low (~30%); primarily binds to albumin and oxytocin-specific carrier proteins (e.g., neurophysin I).
Negligible (<1%); does not bind significantly to plasma proteins.
0.2–0.3 L/kg; reflects limited distribution into extracellular fluid and minimal tissue binding.
0.04–0.06 L/kg; limited distribution, primarily in extracellular fluid.
Intramuscular: ~20–40% (due to rapid enzymatic degradation); Intravenous: 100%.
Intramuscular: approximately 80%; intranasal: highly variable (1–15%).
No dosage adjustment required for renal impairment; oxytocin is rapidly metabolized and renally excreted, but no specific GFR-based guidelines exist.
No dose adjustment required for renal impairment; oxytocin is not significantly renally excreted.
No dosage adjustment required for hepatic impairment; oxytocin is metabolized primarily by the liver, but no Child-Pugh based modifications have been established.
No specific dose adjustment guidelines for hepatic impairment; oxytocin is rapidly metabolized in plasma and liver, dose adjustment not required for Child-Pugh class A, B, or C.
Not indicated for pediatric use; safety and efficacy in children have not been established.
Not indicated for pediatric use; no weight-based dosing established.
Use with caution in elderly patients due to potential for uterine hyperstimulation and adverse cardiovascular effects; no specific dosage adjustments recommended.
No specific elderly dose adjustment; use standard adult dosing with caution in elderly due to potential cardiovascular effects, monitor fluid balance closely.
NOT FOR ELECTIVE INDUCTION OF LABOR AT TERM DUE TO RISK OF UTERINE HYPERSTIMULATION, UTERINE RUPTURE, AND FETAL DISTRESS. SHOULD ONLY BE USED UNDER CONTINUOUS MEDICAL SUPERVISION WITH FETAL AND UTERINE MONITORING.
WARNING: Oxytocin should be administered only by trained personnel in a hospital setting with immediate availability of a physician. Prolonged or high-dose use can cause uterine hyperstimulation, tetanic contractions, uterine rupture, postpartum hemorrhage, and water intoxication (hyponatremia). Fetal heart rate must be monitored continuously.
Uterine hyperstimulation and tetany,Uterine rupture, especially in grand multipara or with prior cesarean,Water intoxication and hyponatremia due to antidiuretic effect (high doses),Fetal bradycardia, hypoxia, and neonatal jaundice,Hypotension and tachycardia with rapid IV administration
Uterine hyperstimulation may lead to fetal distress, uterine rupture, or amniotic fluid embolism. Water intoxication (hyponatremia) can occur with prolonged infusion and antidiuretic effect. Monitor uterine activity, fetal heart rate, and fluid balance. Use with caution in grand multiparity, cervical insufficiency, or prior uterine surgery.
Hypersensitivity to oxytocin or any component,Cephalopelvic disproportion,Fetal distress where delivery is not imminent,Prolapsed umbilical cord,Placenta previa,Vasa previa,Contraindicated for elective induction in term pregnancies
Hypersensitivity to oxytocin, significant cephalopelvic disproportion, unfavorable fetal position, fetal distress where delivery not imminent, preterm labor, active genital herpes, placental previa, vasa previa, cord prolapse, invasive cervical cancer, hypertonic uterus, prior uterine scar (relative), and when vaginal delivery is contraindicated.
No food interactions are known. However, because oxytocin can cause water retention, advise moderate sodium intake to reduce risk of hyponatremia. No specific dietary restrictions.
No significant food interactions. Maintain normal hydration unless instructed otherwise. Avoid large meals immediately before administration to reduce risk of nausea/vomiting.
Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bradycardia, and neonatal hyperbilirubinemia. No trimester-specific malformation risk is established; uterine hyperstimulation risk is greatest during second and third trimester use.
Oxytocin is not teratogenic in humans. First trimester: No increased risk of major malformations. Second and third trimesters: No evidence of teratogenicity; used therapeutically for induction/augmentation of labor. Risks are related to uterine hyperstimulation and fetal hypoxia, not structural anomalies.
Oxytocin is endogenous in breast milk; exogenous administration does not significantly increase milk levels. M/P ratio not clinically relevant due to rapid metabolism. Considered compatible with breastfeeding.
Oxytocin is endogenous in breast milk. Exogenous oxytocin given postpartum is rapidly cleared; minimal transfer to infant via milk. No adverse effects reported. M/P ratio is not applicable due to endogenous production; exogenous levels are negligible.
No standard dose adjustment required due to pregnancy-induced pharmacokinetic changes. However, uterine sensitivity to oxytocin increases with gestational age; lower starting doses may be used near term to avoid hyperstimulation.
No dose adjustment needed based on pregnancy-related pharmacokinetic changes. Oxytocin is administered intravenously with dose titration to achieve adequate uterine contractions, starting at low doses (0.5-2 m U/min) and increasing as needed. Pregnancy does not alter its metabolism or clearance significantly.
Syntocinon (oxytocin) is used for induction or augmentation of labor. Administer via controlled IV infusion using an infusion pump. Start at 0.5-2 m U/min and titrate every 30-60 min to achieve adequate contractions (3-5 per 10 min). Monitor for uterine hyperstimulation, fetal distress, or water intoxication (antidiuretic effect). Have magnesium sulfate, terbutaline, or other tocolytics available for hyperstimulation. Do not use if contraindicated (e.g., cephalopelvic disproportion, fetal distress, placenta previa).
Use undiluted 10 IU/m L solution for postpartum hemorrhage; administer slowly (0.5-1 m L/min) to avoid hypotension. Dilute in NS or LR for induction/augmentation. Do not use in patients with significant cephalopelvic disproportion or fetal distress. Monitor uterine activity and fetal heart rate continuously. Have magnesium sulfate and nifedipine available for hyperstimulation. Store at room temperature; do not freeze.
Syntocinon is given intravenously to start or strengthen labor contractions.,You will be closely monitored with an electronic fetal monitor.,Report any excessively frequent or prolonged contractions or severe pain immediately.,It may increase the risk of postpartum hemorrhage; staff is prepared to manage it.,Tell your healthcare provider about any history of heart disease or high blood pressure.
This medication is used to start or strengthen labor contractions, or to control bleeding after childbirth.,You will receive this as an injection or through an IV line under close monitoring.,Common side effects include nausea, vomiting, and headache; report excessive pain or prolonged contractions.,Inform your healthcare provider if you have a history of heart disease, high blood pressure, or prior uterine surgery.,Avoid sudden movements if receiving IV; alert staff if you feel lightheaded or have chest pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNTOCINON vs OXYTOCIN, answered by our medical review team.
SYNTOCINON is a Oxytocic that works by Synthetic oxytocin binds to oxytocin receptors in the myometrium, causing increased intracellular calcium and uterine smooth muscle contraction. Also acts on mammary gland myoepithelium for milk ejection.. OXYTOCIN is a Oxytocic that works by Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, stimulating G-protein coupled receptor activation and increasing intracellular calcium, leading to uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to induce milk ejection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNTOCINON and OXYTOCIN depend on the specific clinical indication. These are both Oxytocic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNTOCINON is: 10 units (1 m L) intravenously as a single dose after delivery; continuous infusion: 20 units in 1 L of normal saline or lactated Ringer's solution at 2-10 m U/min (0.1-0.5 m L/min) titrated to uterine response.. The standard adult dose of OXYTOCIN is: For induction/augmentation of labor: IV infusion, initial 0.5-2 m U/min, increase by 1-2 m U/min every 30-60 min until desired contraction pattern; max 20 m U/min. For postpartum hemorrhage: IV bolus 3 units (slow push) or IV infusion 10-40 units in 1000 m L crystalloid, rate adjusted to control bleeding; alternatively IM 10 units after delivery of placenta.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNTOCINON and OXYTOCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNTOCINON is classified as Category C. Syntocinon (oxytocin) is not associated with teratogenic effects when used at standard doses for labor induction. However, prolonged high-dose exposure may cause fetal hypoxia, bra. OXYTOCIN is classified as Category C. Oxytocin is not teratogenic in humans. First trimester: No increased risk of major malformations. Second and third trimesters: No evidence of teratogenicity; used therapeutically f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.